Cryptococcosis is one of the leading community-acquired opportunistic mycoses (10, 11, 20, 21, 23, 29, 33) . Although serious disease (e.g., meningitis and cryptococcemia) may occur in healthy hosts, the majority of infections occur in patients with significant underlying predisposing factors, such as organ transplantation, hematologic malignancies, and advanced human immunodeficiency virus disease, particularly those not receiving highly active antiretroviral therapy (HAART) (20, 21, 33) . Pharmacologic management of cryptococcal infections usually consists of primary therapy with amphotericin B, with or without flucytosine, followed by maintenance therapy, or in some instances life-long suppressive therapy, with fluconazole (43) . High rates of fungal persistence and frequent disease relapse have sparked a growing concern among clinicians regarding the potential for the emergence of antifungal resistance among Cryptococcus neoformans (8, 11) .
There are now several published reports of the emergence of resistance to amphotericin B, fluconazole, flucytosine, or itraconazole in C. neoformans during treatment (7, 9-11, 14, 15, 17, 24, 34, 42) . Most of these reports involve resistance to fluconazole emerging in the setting of meningitis in AIDS patients after long treatments or prophylaxis with fluconazole (7, 8, 34) . Recent reports from Cambodia (12, 44) and from India (16) have raised the concern of a more widespread increase in fluconazole resistance among C. neoformans, suggesting the need for greater vigilance and more-widespread surveillance.
Although antifungal resistance surveillance with a focus on Candida spp. is now widespread (39, 40) , similar programs providing temporal and geographic data regarding the antifungal susceptibility of C. neoformans isolates are quite limited. Studies by Brandt et al. (11) , Davey et al. (17) , Klepser and Pfaller (25) , and Yildiran et al. (48) provide in vitro antifungal susceptibility data generated by National Committee for Clinical Laboratory Standards (NCCLS) reference MIC methods (30) , indicating that in vitro resistance to commonly used antifungal agents (i.e., amphotericin B, flucytosine, fluconazole, and itraconazole) remains uncommon among C. neoformans and has not increased with time in the last decade in the United States and in the United Kingdom. In contrast, Sar et al. (44) report an increase in resistance to fluconazole from 2.5% to 14% between 2001 and 2002 in a hospital in Cambodia. Both Archibald et al. (6) and Datta et al. (16) stress the need for expanded international surveillance of antifungal susceptibility of cryptococcal isolates; however, the published literature thus far is limited to small studies of limited geographic scope conducted over rather short periods of time (2, 6, 12-14, 16, 18, 41, 44) .
At the University of Iowa, we have conducted surveillance of cryptococcosis (i.e., meningitis and cryptococcemia) using a consistent protocol (consecutive incident isolates, one per patient, multiple institutions) and standardized reference quality identification and antifungal susceptibility testing methods from 1990 up to the present (25, 37, 38, 47) . This cumulative experience allows us to examine change in the in vitro suscep-tibility of C. neoformans to commonly used antifungal agents (amphotericin B, flucytosine, fluconazole) spanning a 15-year period and representing 100 medical centers in five geographic regions throughout the world. In addition, this diverse collection of clinically significant isolates provides the opportunity for a head-to-head comparison of the activities of the "expanded-spectrum" triazoles, voriconazole, posaconazole, and ravuconazole. Table 2) .
MATERIALS AND METHODS

Organisms
The isolates were identified by standard methods (22) and were stored as water suspensions until used. Upon receipt at the University of Iowa, the isolates were subcultured onto potato dextrose agar not containing antibiotics (Remel, Lenexa, KS) and CHROMagar Candida medium (Hardy Laboratories, Santa Maria, CA) to ensure viability and purity. Identifications were reconfirmed with Vitek and API yeast identification systems (bioMérieux, St. Louis, MO).
Antifungal agents. Standard antifungal powders of amphotericin B (Sigma), flucytosine (Sigma), fluconazole (Pfizer, New York, NY), voriconazole (Pfizer), posaconazole (Schering-Plough, Kenilworth, NJ), and ravuconazole (Bristol- final concentration were dispensed into wells of plastic microdilution trays by using a Quick Spense II System (Dynatech Laboratories, Chantilly, VA). The trays were sealed and frozen at Ϫ70°C until they were used. Antifungal susceptibility studies. Broth microdilution testing was performed in accordance with the guidelines in NCCLS document M27-A2 (30), using RPMI 1640 medium, a final inoculum concentration of (1.5 Ϯ 1.0) ϫ 10 3 cells/ml, and incubation at 35°C for 72 h. The final concentrations of the antifungal agents were 0.12 to 128 g/ml for fluconazole, 0.06 to 128 g/ml for flucytosine, and 0.007 to 8 g/ml for all other agents. Drug-free and yeast-free controls were included.
Following incubation, the MICs of fluconazole, flucytosine, voriconazole, posaconazole, and ravuconazole were read as the lowest concentration at which a prominent decrease (approximately 50%) in turbidity relative to the turbidity of the growth control was observed (30) . Amphotericin B MICs were determined to be at 100% inhibition relative to the growth control. Quality control was performed by testing the NCCLS-recommended strains C. krusei ATCC 6258 and C. parapsilosis ATCC 22019 (30) .
The interpretive criteria for susceptibility to fluconazole and flucytosine were those published by the NCCLS (30): for fluconazole, susceptible, Յ8 g/ml; susceptible dose dependent, 16 to 32 g/ml; resistant, Ն64 g/ml; for flucytosine, susceptible, Յ4 g/ml; intermediate, 8 to 16 g/ml; resistant, Ն32 g/ml. Interpretive criteria have not yet been approved for amphotericin B, voriconazole, posaconazole, or ravuconazole. As suggested by Nguyen and Yu (32) and Lozano-Chiu et al. (26) , isolates for which amphotericin B MICs were Ն2 g/ml were considered resistant (Յ1 g/ml, susceptible). For purposes of comparison and because preliminary pharmacokinetic data indicated that levels of voriconazole, posaconazole, and ravuconazole achievable in serum may range from 2 to 6 g/ml (3-5, 19, 36), we have used a breakpoint for susceptibility of Յ1 g/ml for all three agents.
RESULTS AND DISCUSSION
During the 15-year study period (1990 to 2004), a total of 1,811 clinical isolates (episodes) of C. neoformans were submitted by 100 study centers in Africa, Europe, Latin America, the Pacific, and North America (Table 1 ). Resistance to the three commonly used antifungal agents, amphotericin B, flucytosine, and fluconazole, was Յ1% overall (Table 1) . Between 98 and 100% of isolates were susceptible (MIC, Յ1 g/ml) to amphotericin B irrespective of geographic region. In contrast, susceptibility to flucytosine (MIC, Յ4 g/ml) ranged from 35% in North America to 68% in Latin America (Table 1) . Likewise, only 75% of isolates from North America were susceptible to fluconazole (MIC, Յ8 g/ml), compared to 94 to 100% in the other regions.
Aller et al. (1) have shown that a more-positive clinical response to fluconazole maintenance therapy could be expected when the fluconazole MIC is Ͻ16 g/ml than when the MIC is Ն16 g/ml for the infecting C. neoformans strain. Using this "surrogate breakpoint," 25% of North American isolates demonstrate decreased susceptibility (MIC, Ն16 g/ml) compared to 0 to 6% of isolates from the other four geographic regions (Table 1) . Table 2 summarizes the in vitro susceptibilities to the three antifungal agents in use throughout the 15-year period (amphotericin B, flucytosine, and fluconazole) of C. neoformans from all areas stratified by 5-year time intervals. Isolates remained highly susceptible to amphotericin B (99% susceptible at MIC of Յ1 g/ml) over the entire 15-year period. In contrast, susceptibility to flucytosine (MIC, Յ4 g/ml) increased from 34% in 1990 to 1994 to 38% in 1995 to 1999 and 66% in 2000 to 2004 (Table 2) . A similar trend was seen with fluconazole, where the percentage of isolates susceptible at a MIC of Յ8 g/ml increased from 72% in 1990 to 1994 to 89% in 1995 to 1999 and 96% in 2000 to 2004 (Table 2) . High-level resistance to flucytosine (MIC, Ն32 g/ml) and to fluconazole (MIC, Ն64 g/ml) remained essentially unchanged at 1 to 2% over the entire study period, indicating that the apparent improvement in susceptibility to flucytosine and fluconazole over time was due to a shift of isolates from the intermediate or susceptible dose-dependent category, respectively, to the susceptible category.
These data address the concerns of Archibald et al. (6) and Datta et al. (16) regarding the need for expanded surveillance involving international sites (Table 1) (48) that high-level resistance to commonly used antifungal agents among isolates of C. neoformans is uncommon and has not increased over time (Table 2) . Notably, we have shown that isolates of C. neoformans from North America are considerably less susceptible to both flucytosine and fluconazole than isolates from other geographic regions. The reasons for these differences are not immediately apparent; however, greater accessibility and exposure to both of these agents in North America versus other regions may account for some of the difference.
The apparent improvement in susceptibility of C. neoformans over time to both flucytosine and fluconazole is notable and may reflect in part a decrease in the overall drug pressure due to these agents concomitant with a decrease in cryptococcosis among human immunodeficiency virus-infected individuals receiving HAART. A similar improvement in fluconazole susceptibility among Candida albicans isolates from AIDS patients has been noted following the introduction of HAART (27) . It was suggested that decreased use of antifungal agents in patients treated with effective antiretroviral therapy may have contributed to the decrease in fluconazole-resistant strains colonizing and infecting these individuals (27) .
Although the overall picture regarding the susceptibility of C. neoformans to the standard therapeutic agents shown in Tables 1 and 2 is quite positive, it is reasonable to explore new and alternative therapies for cryptococcosis (33) . The three new extended-spectrum triazoles, voriconazole, posaconazole, and ravuconazole, all have potent in vitro activity against this large, globally diverse collection of C. neoformans isolates (Table 3). Overall, 99% of all isolates tested were susceptible to these three agents at a MIC of Յ1 g/ml (Table 3) . The rare strains for which the MICs for fluconazole were Ն64 g/ml also exhibited MICs of 2 to 4 g/ml for the three extendedspectrum triazoles (data not shown). This potent activity suggests that these new agents may be useful as alternative therapies for cryptococcosis. Notably, both voriconazole and posaconazole have been shown to be useful in treating other central nervous system mycoses (28, 31, 35, 45, 46) . In summary, we have confirmed that in vitro resistance to standard antifungal agents used in the treatment of cryptococcosis remains uncommon among isolates of C. neoformans from five broad geographic regions and has not increased over VOL. 43, 2005 SURVEILLANCE OF C. NEOFORMANS 2165 a 15-year period. We have shown that clinical isolates of C. neoformans from Africa, Europe, Latin America, and the Pacific regions are more susceptible to both flucytosine and fluconazole than isolates from North America. The susceptibility trend over time, however, indicates an overall shift to greater susceptibility of isolates to both flucytosine and fluconazole, possibly influenced by effective antiretroviral therapy and a decreased incidence of cryptococcosis. Finally, we provide the most extensive evidence to date of the excellent potencies of voriconazole, posaconazole, and ravuconazole against clinical isolates of C. neoformans. Despite these favorable findings, continued surveillance for emerging resistance may be warranted given the global importance of this organism as an opportunistic pathogen and the ever-increasing use of antifungal agents in the immunocompromised patient population. 
